WALTHAM, Mass.—(BUSINESS WIRE)—Jan. 5, 2017—OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Michelle Dipp, M.D., Ph.D., Executive Chair and Co-founder of OvaScience, will present a corporate overview at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 8:30 a.m. PT (11:30 a.m. ET) at the Westin St. Francis Hotel in San Francisco, California.
A live audio webcast of the presentation can be accessed by visiting the investor section of the company’s website at www.ovascience.com. A replay of the webcast will be archived on the OvaScience website for 30 days following the presentation.
OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC℠) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing the OvaPrime℠ treatment, which could increase a woman’s egg reserve, and the OvaTure℠ treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience’s AUGMENT℠ treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in select international regions. OvaScience treatments are not available in the U.S. For more information, visit www.ovascience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105006300/en/
Source: OvaScience, Inc.
Jennifer Viera, 617-420-8748